Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Takami Sato

Showing results (11-20 of 114) with videos related to

Pageof 12
Sort By:
Cancer Gene Therapy|March 3, 2022
Review of bi-specific therapies in uveal melanomaMarlana Orloff, Rino Seedor, Takami Sato
Cancer Immunology, Immunotherapy : CII|July 12, 2002
Effect of the dose and composition of an autologous hapten-modified melanoma vaccine on the development of delayed-type hypersensitivity responsesDavid Berd, Takami Sato, Michael J Mastrangelo
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 20, 2005
Calculation of survival of patients with stage III melanomaDavid Berd, Michael J Mastrangelo, Takami Sato
Expert Opinion on Investigational Drugs|June 13, 2015
Successes and setbacks of early investigational drugs for melanomaMarlana Orloff, Matias E Valsecchi, Takami Sato
Cancers|November 13, 2021
Genetic Landscape and Emerging Therapies in Uveal MelanomaRino S Seedor, Marlana Orloff, Takami Sato
Seminars in Interventional Radiology|January 18, 2014
Transhepatic therapies for metastatic uveal melanomaDavid J Eschelman, Carin F Gonsalves, Takami Sato
Cancers|November 13, 2021
The Role of HGF/MET Signaling in Metastatic Uveal MelanomaRyota Tanaka, Mizue Terai, Eric Londin, et al.
Journal of Immunology (Baltimore, Md. : 1950)|September 10, 2002
TCR rearrangement in lymphocytes infiltrating melanoma metastases after administration of autologous dinitrophenyl-modified vaccineJayanthi Manne, Michael J Mastrangelo, Takami Sato, et al.
Reviews on Recent Clinical Trials|March 31, 2016
Immune Check Point Inhibitors Combination in Melanoma: Worth the Toxicity?Marlana Orloff, Ryan Weight, Matias E Valsecchi, et al.
Melanoma Research|July 13, 2007
A pilot study of low-dose thalidomide and interferon alpha-2b in patients with metastatic melanoma who failed prior treatmentMagdolna Solti, David Berd, Michael J Mastrangelo, et al.
Pageof 12

Showing results (11-20 of 114) with videos related to

Sort By:
Pageof 12
Cancer Gene Therapy|March 3, 2022
Review of bi-specific therapies in uveal melanomaMarlana Orloff, Rino Seedor, Takami Sato
Cancer Immunology, Immunotherapy : CII|July 12, 2002
Effect of the dose and composition of an autologous hapten-modified melanoma vaccine on the development of delayed-type hypersensitivity responsesDavid Berd, Takami Sato, Michael J Mastrangelo
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 20, 2005
Calculation of survival of patients with stage III melanomaDavid Berd, Michael J Mastrangelo, Takami Sato
Expert Opinion on Investigational Drugs|June 13, 2015
Successes and setbacks of early investigational drugs for melanomaMarlana Orloff, Matias E Valsecchi, Takami Sato
Cancers|November 13, 2021
Genetic Landscape and Emerging Therapies in Uveal MelanomaRino S Seedor, Marlana Orloff, Takami Sato
Seminars in Interventional Radiology|January 18, 2014
Transhepatic therapies for metastatic uveal melanomaDavid J Eschelman, Carin F Gonsalves, Takami Sato
Cancers|November 13, 2021
The Role of HGF/MET Signaling in Metastatic Uveal MelanomaRyota Tanaka, Mizue Terai, Eric Londin, et al.
Journal of Immunology (Baltimore, Md. : 1950)|September 10, 2002
TCR rearrangement in lymphocytes infiltrating melanoma metastases after administration of autologous dinitrophenyl-modified vaccineJayanthi Manne, Michael J Mastrangelo, Takami Sato, et al.
Reviews on Recent Clinical Trials|March 31, 2016
Immune Check Point Inhibitors Combination in Melanoma: Worth the Toxicity?Marlana Orloff, Ryan Weight, Matias E Valsecchi, et al.
Melanoma Research|July 13, 2007
A pilot study of low-dose thalidomide and interferon alpha-2b in patients with metastatic melanoma who failed prior treatmentMagdolna Solti, David Berd, Michael J Mastrangelo, et al.
Pageof 12